Chemomab Therapeutics (NASDAQ:CMMB) Shares Up 4.7% – Should You Buy?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) shot up 4.7% during trading on Thursday . The company traded as high as $1.84 and last traded at $1.80. 31,693 shares were traded during mid-day trading, a decline of 35% from the average session volume of 48,497 shares. The stock had previously closed at $1.72.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $25.00.

Chemomab Therapeutics Price Performance

The company has a market cap of $12.73 million, a PE ratio of -0.80 and a beta of 0.62. The stock’s 50-day moving average is $1.70 and its 200 day moving average is $1.84.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.18). On average, analysts expect that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Chemomab Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CMMB. ADAR1 Capital Management LLC purchased a new position in shares of Chemomab Therapeutics in the 4th quarter valued at approximately $132,000. Kestra Private Wealth Services LLC purchased a new position in shares of Chemomab Therapeutics in the 4th quarter valued at approximately $85,000. Finally, XTX Topco Ltd purchased a new position in shares of Chemomab Therapeutics in the 4th quarter valued at approximately $31,000. 46.05% of the stock is owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.